NASDAQ$RXST
Rxsight Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Reported financial results for the second quarter of 2021.
RxSight reported second quarter 2021 revenue of $4.9 million, representing growth of 81% compared to the prior year period. The growth was primarily driven by increased LDD and LAL unit sales and a more favorable market environment because of the reduced impact from the COVID-19 pandemic. Net loss was $(13.5) million, or $(3.28) and $(3.53) per share on a basic and diluted basis, respectively.
- Achieved second quarter 2021 revenue of $4.9 million, representing growth of 81% compared to the prior year period.
- Sale of 25 Light Delivery Devices (LDD™s), expanding the installed base to 130 LDDs as of June 30, 2021.
- Sale of 1,825 Light Adjustable Lenses (LAL®s)
- Completed an initial public offering (IPO) in July raising approximately $120 million of net proceeds.
Headline financials
Revenue & EPS history
Rxsight · Revenue · Quarterly
$4.9M
Revenue by segment
Rxsight · $11.4M total across 2 segments · Q2 2022
- LAL Revenue$5.8M—50.9%
- LDD Revenue$5.6M—49.1%
Forward guidance
This press release contains forward-looking statements, including those related physician adoption of the RxSight Light Adjustable Lens system, optimal outcomes for patients, the ability to deliver the visual acuity and quality patients expect and the ability to overcome one of the major factors that has limited growth of the premium market with the RxSight Adjustable Lens system, the ability to continue advancement of the RxSight technology and the ability of the IPO proceeds to fill the resource needs for growth in the Company’s business.
Tailwinds
- Physician adoption of the RxSight Light Adjustable Lens system
- Optimal outcomes for patients
- The ability to deliver the visual acuity and quality patients expect
- The ability to overcome one of the major factors that has limited growth of the premium market with the RxSight Adjustable Lens system
- The ability to continue advancement of the RxSight technology
Headwinds
- Our ability to maintain cash balances
- Successfully commercialize or partner our product candidates currently under development.
- Our future financial performance
- In some cases, you can identify forward-looking statements by terminology such as 'may,' 'will,' 'should,' 'could,' 'would,' 'expects,' 'plans,' 'intends,' 'anticipates,' 'believes,' 'estimates,' 'predicts,' 'projects,' 'potential,' or 'continue' or the negative of such terms and other same terminology.
- Actual events or results may differ materially.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports
-1.1%
Avg return
Earnings day
-2.6%
Avg return
5 days after
+2.8%
Avg return
30 days after
45%
9 / 20 earnings
Positive
+15.1%
Q3 2022
Best reaction
-16.1%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -6.6% | -21.6% | -31.1% | |
| Q4 2025 | -10.1% | -13.5% | -28.9% | |
| Q3 2025 | +8.7% | +16.3% | +46.7% | |
| Q1 2025 | -11.2% | -11.4% | +0.9% | |
| Q4 2024 | -0.8% | -7.8% | -9.1% | |
| Q3 2024 | -12.3% | -16.9% | -21.2% | |
| Q2 2024 | +14.6% | +21.5% | +29.0% | |
| Q1 2024 | +0.8% | -3.8% | -5.0% | |
| Q4 2023 | -5.8% | -3.2% | -10.9% | |
| Q3 2023 | +1.8% | +9.5% | +40.8% | |
| Q2 2023 | -1.5% | -6.3% | -1.8% | |
| Q1 2023 | +9.0% | +18.3% | +34.0% | |
| Q4 2022 | +9.7% | +4.5% | +17.9% | |
| Q3 2022 | +15.1% | +14.6% | +18.1% | |
| Q2 2022 | -2.9% | -8.3% | -13.3% | |
| Q1 2022 | -4.3% | -3.0% | +34.9% | |
| Q4 2021 | +1.4% | -3.2% | +1.8% | |
| Q3 2021 | +3.7% | -0.8% | -4.0% | |
| Q4 2020 | -16.1% | -18.4% | -21.1% | |
| Q2 2021 | -16.1% | -18.4% | -21.1% | |
| Q1 2021 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro